Managing Hypertriglyceridemia with Olezarsen, an oligonucleotide that neutralize Apoprotein C-III mNRA
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on May 29th, 2024
|
Hypertriglyceridemia is associated with severe health outcomes such as acute pancreatitis, and there are currently not many available pharmaceutical interventions. Apoprotein C-III (APOC3) is a naturally producing agent that increases the level of triglycerides in blood by inhibiting lipoprotein lipase and hepatic clearance. Therefore, a new study was conducted to assess the effect of Olezarsen, a oligonucleotide that can neutralize APOC3 mRNA, in managing hypertriglyceridemia.
The phase 2 clinical trial included 154 patients who had previously been diagnosed with moderate-to-severe hypertriglyceridemia and have a median triglyceride level of approximately 230 mg/dL. At baseline, the median APOC3 and VLDL cholesterol levels were around 15 mg/dL and 40 mg/dL, respectively. More than 80% of the cohort was using statin to manage their condition. The participants were randomly assigned to receive monthly subcutaneous injection of placebo or olezarsen at 2 dose-levels: 50 mg and 80 mg. When compared to the placebo, 12-month usage of both 50 and 80 mg of olezarsen reduced the triglyceride level to around half of the baseline level. In fact, significant reduction was observed within the first 28 days of the study, and around 90% of those who were treated with olezarsen were considered to have a normal triglyceride level by the sixth month. Additionally, olezarsen usage also decreased the median level of APOC3, VLDL cholesterol, and increased the level of HDL cholesterol.
The phase 2 clinical trial included 154 patients who had previously been diagnosed with moderate-to-severe hypertriglyceridemia and have a median triglyceride level of approximately 230 mg/dL. At baseline, the median APOC3 and VLDL cholesterol levels were around 15 mg/dL and 40 mg/dL, respectively. More than 80% of the cohort was using statin to manage their condition. The participants were randomly assigned to receive monthly subcutaneous injection of placebo or olezarsen at 2 dose-levels: 50 mg and 80 mg. When compared to the placebo, 12-month usage of both 50 and 80 mg of olezarsen reduced the triglyceride level to around half of the baseline level. In fact, significant reduction was observed within the first 28 days of the study, and around 90% of those who were treated with olezarsen were considered to have a normal triglyceride level by the sixth month. Additionally, olezarsen usage also decreased the median level of APOC3, VLDL cholesterol, and increased the level of HDL cholesterol.